Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

Key Points

• Efimosfermin alfa significantly improved fibrosis scores in participants with metabolic dysfunction-associated steatohepatitis.
• Participants received doses for 24 weeks, enhancing liver health with a specific focus on fibrosis stages F2 and F3.
• This randomised, double-blind, placebo-controlled trial involved individuals diagnosed with steatohepatitis and relevant fibrosis.
• Study underscores potential new treatment pathways for metabolic liver diseases, although further research is necessary.